Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

Amy V Rapkiewicz, Xingchen Mai, Steven E Carsons, Stefania Pittaluga, David E Kleiner, Jeffrey S Berger, Sarun Thomas, Nicole M Adler, David M Charytan, Billel Gasmi, Judith S Hochman, Harmony R Reynolds, Amy V Rapkiewicz, Xingchen Mai, Steven E Carsons, Stefania Pittaluga, David E Kleiner, Jeffrey S Berger, Sarun Thomas, Nicole M Adler, David M Charytan, Billel Gasmi, Judith S Hochman, Harmony R Reynolds

Abstract

Background: There is increasing recognition of a prothrombotic state in COVID-19. Post-mortem examination can provide important mechanistic insights.

Methods: We present a COVID-19 autopsy series including findings in lungs, heart, kidneys, liver, and bone, from a New York academic medical center.

Findings: In seven patients (four female), regardless of anticoagulation status, all autopsies demonstrated platelet-rich thrombi in the pulmonary, hepatic, renal, and cardiac microvasculature. Megakaryocytes were seen in higher than usual numbers in the lungs and heart. Two cases had thrombi in the large pulmonary arteries, where casts conformed to the anatomic location. Thrombi in the IVC were not found, but the deep leg veins were not dissected. Two cases had cardiac venous thrombosis with one case exhibiting septal myocardial infarction associated with intramyocardial venous thrombosis, without atherosclerosis. One case had focal acute lymphocyte-predominant inflammation in the myocardium with no virions found in cardiomyocytes. Otherwise, cardiac histopathological changes were limited to minimal epicardial inflammation (n = 1), early ischemic injury (n = 3), and mural fibrin thrombi (n = 2). Platelet-rich peri‑tubular fibrin microthrombi were a prominent renal feature. Acute tubular necrosis, and red blood cell and granular casts were seen in multiple cases. Significant glomerular pathology was notably absent. Numerous platelet-fibrin microthrombi were identified in hepatic sinusoids. All lungs exhibited diffuse alveolar damage (DAD) with a spectrum of exudative and proliferative phases including hyaline membranes, and pneumocyte hyperplasia, with viral inclusions in epithelial cells and macrophages. Three cases had superimposed acute bronchopneumonia, focally necrotizing.

Interpretation: In this series of seven COVID-19 autopsies, thrombosis was a prominent feature in multiple organs, in some cases despite full anticoagulation and regardless of timing of the disease course, suggesting that thrombosis plays a role very early in the disease process. The finding of megakaryocytes and platelet-rich thrombi in the lungs, heart and kidneys suggests a role in thrombosis.

Funding: None.

Keywords: “Autopsy”; “COVID-19″; “Megakaryocyte”; “Thrombosis”.

Conflict of interest statement

Dr. Rapkiewicz, Dr. Mai, Dr. Pittaluga, Dr. Thomas, Dr. Kleiner, Dr. Adler and Dr. Gasmi have nothing to disclose. Dr. Carsons reports grants from Novartis and grants from GSK, outside the submitted work. Dr. Berger reports grants from National Heart, Lung and Blood Institute, during the conduct of the study; grants from Astrazeneca, other from Jannsen, other from Amgen, outside the submitted work. Dr. Charytan reports personal fees from PLC Medical, grants from bioporto, personal fees from Merck, grants and personal fees from NovoNordisk, grants and personal fees from Jannssen, grants and personal fees from Gilead, personal fees from AstraZeneca, grants and personal fees from Medtronic, grants and personal fees from Amgen, personal fees from Fresenius, personal fees from GSK, outside the submitted work. Dr. Hochman was supported in part by the NYU CTSA grant UL1TR001445, from the National Center for Advancing Translational Sciences (NCATS) during the conduct of the study; grants from NHLBI, other from AstraZeneca Pharmaceuticals LLC, other from Arbor Pharmaceuticals LLC, non-financial support from Abbott Vascular, non-financial support from Medtronic Inc, non-financial support from St. Jude Medical Inc, non-financial support from Volcano Corp, non-financial support from Merck Sharp & Dohme Corp, non-financial support from Omron Healthcare Inc, non-financial support from Amgen Inc, outside the submitted work. Dr. Reynolds reports non-financial support from Abbott Vascular, non-financial support from Siemens, non-financial support from Biotelemetry Inc outside the submitted work.

© 2020 Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Thrombosis in multiple organs at autopsy. Panel A, Case 3, 20x magnification of hematoxylin and eosin stained section, medium vessel pulmonary artery thrombus (yellow star) with lines of Zahn and fibrin thrombus without organization in a smaller arteriole (yellow arrow). The adjacent lung shows similar temporal relationship with exudative phase of diffuse alveolar damage with hyaline membrane formation. Panel B, Case 2, 20x magnification of hematoxylin and eosin stained section of medulla of the kidney with fibrin microthrombi in the peritubular capillaries (black arrows). The tubular epithelium shows detachment from the basement membrane with vacuolization as well as granular debris within the tubular lumen. Panel C, Case 7, 20x magnification of hematoxylin and eosin stained section. Cardiac tissue with fibrin thrombus in a perforating vein (blue arrow) associated with a myocardial infarction showing myocardial necrosis, which was transmural, and neutrophilic infiltrates. Panel D, Case 2, 10x magnification of hematoxylin and eosin stained section. Platelet microthrombi highlighted by CD61 immunohistochemical stain within the microvasculature of the lung. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 2
Fig. 2
Pulmonary thrombi. Panel A: Case 4, Large occlusive pulmonary thrombus within the right main pulmonary artery (white arrow). Panel B: Case 4, Thrombus easily removed showing a predominately white thrombus that is molded in the anatomic pattern of the pulmonary vasculature. Panel C: Case 5, Loosely adherent pulmonary thrombus within a segmental pulmonary artery of the left lung (blue arrow). Panel D: Case 5, H&E 40x, microscopic image of the lung showing changes of diffuse alveolar damage as well as a fibrin microthrombus (yellow star). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3
Fig. 3
Megakaryocytes in the heart, kidney, lung and bone marrow. Panel A: Case 4, 40x H&E stain, Heart with early ischemic changes and megakaryocyte (yellow arrow) and fibrin thrombus within the lumen of a venule. Panel B: Case 2, 20x H&E stain, Lung with pulmonary edema and early bronchopneumonia with multiple megakaryocytes (black arrows) within the alveolar capillaries. Panel C: Case 4, 20x H&E stain, Megakaryocyte within the capillary loop of a glomerulus (blue arrow). Panel D: Case 3, Hypercellular marrow for age with trilineage hematopoiesis. There is an increased number of megakaryocytes with focal clustering (green arrows). Myeloid elements show only focal evidence of progressive maturation (left shift). Megakaryocytes and platelets are highlighted by CD61 staining. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 4
Fig. 4
Myocardial Inflammation and Right Ventricular Mural Thrombus (Case 4). Panels A and B: H&E 10x, Myocardium with a focal chronic inflammatory infiltrate composed of lymphocytes with associated myocardial necrosis in the epicardial region (yellow stars). Panel C: Platelet microthrombi highlighted by CD61 immunohistochemical stain within the microvasculature of the heart (yellow arrows), 10x. Panel D: Gross image of a cut section of the heart showing transmural diffuse pallor of the left ventricle. Panel E: Right ventricle of the heart with mural white thrombus within the trabeculae carnae. Panel F: Microscopic findings in the right ventricle of the heart with mural white thrombus within the trabeculae carnae. Panel G: Admission ECG shows normal sinus rhythm without significant ST segment abnormality.
Fig. 5
Fig. 5
Myocardial Infarction due to Venous Thrombosis (Case 7). Panel A: Admission ECG showing normal sinus rhythm. Panel B: ECG after intubation (day of death), showing sinus rhythm with premature atrial contraction and inferolateral ST segment elevation. Panel C: Cut section of left and right ventricle showing pallor with peripheral hemorrhage rim at the juncture of the posterior ventricles and interventricular septum (red star). Panel D: Microscopic section showing megakaryocyte within a small vessel in the myocardium (yellow arrow). Panels E, F, G: H&E sections of the right and left ventricle with intramyocardial venous thrombosis (yellow stars), fibrin microthrombi and varying degrees of infarction.

References

    1. Wang D., Hu B., Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
    1. Chen T., Wu D., Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
    1. Guo T., Fan Y., Chen M. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020:e201017.
    1. Shi S., Qin M., Shen B. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Published online March 25, 2020.
    1. Bangalore S., Sharma A., Slotwiner A. ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med. 2020 NEJMc2009020.
    1. Poissy J., Goutay J., Caplan M. Pulmonary Embolism in COVID-19 Patients: awareness of an Increased Prevalence. Circulation. 2020
    1. Middeldorp S., Coppens M., van Haaps T.F. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020 doi: 10.1111/jth.14888.
    1. Klok F.A., Kruip M., van der Meer N.J.M. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
    1. Bikdeli B., Madhavan M.V., Jimenez D. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–2973.
    1. Lax S.F., Skok K., Zechner P. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020 M20–2566.
    1. Menter T., Haslbauer J.D., Nienhold R. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020 doi: 10.1111/his.14134.
    1. Wichmann D., Sperhake J.P., Lutgehetmann M. Autopsy findings and venous thromboembolism in patients With COVID-19. Ann Intern Med. 2020 May 6 M20–2003.
    1. Magro C., Mulvey J.J., Berlin D. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.
    1. Paranjpe I., Fuster V., Lala A. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. J Am Coll Cardiol. 2020;S0735-1097(20) 35218–9.
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094–1099.
    1. Gattinoni L., Coppola S., Cressoni M., Busana M., Rossi S., Chiumello D. COVID-19 does not lead to a "Typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201:1299–1300.
    1. Barton L.M., Duval E.J., Stroberg E., Ghosh S., Mukhopadhyay S. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153:725–733.
    1. Brill R., Halpern M.M. The frequency of megakaryocytes in autopsy sections. Blood. 1948;3:286–291.
    1. Smith E.B., Butcher J. The incidence, distribution and significance of Megakaryocytes in normal and diseased human tissues. Blood. 1952;7:214–224.
    1. Van Pampus E.C., Huijgens P.C., Zevenbergen A., Verheugt F.W., Langenhuijsen M.M. Circulating human megakaryocytes in cardiac diseases. Eur J Clin Invest. 1994;24:345–349.
    1. Brocklebank V., Wood K.M., Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300–317.
    1. Edler C., Schroder A.S., Aepfelbacher M. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med. 2020:1–10.
    1. Varga Z., Flammer A.J., Steiger P. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418.
    1. Ackermann M., Verleden S.E., Kuehnel M. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2015432.
    1. Fox S.E., Akmatbekov A., Harbert J.L., Li G., Quincy Brown J., Vander Heide R.S. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;S2213-2600(20) 30243–5.
    1. Bradley B.T., Maioli H., Johnston R. Histopathology and ultrastructural findings of fatal COVID-19 infections. medRxiv. 2020 2020.04.17.20058545.
    1. Buja L.M., Wolf D.A., Zhao B. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48
    1. Sala S., Peretto G., Gramegna M. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41:1861–1862.
    1. Paddock C.D., Liu L., Denison A.M. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis. 2012;205:895–905.
    1. Siskin M., Rao S., Rapkiewicz A., Bangalore S., Garshick M. A Case of Cardiogenic Shock Secondary to Complement-Mediated Myopericarditis From Influenza B Infection. Can J Cardiol. 2017;33 1335 e1- e3.
    1. Szekely Y., Lichter Y., Taieb P. The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19) - a Systematic Echocardiographic Study. Circulation. 2020;2020 doi: 10.1161/CIRCULATIONAHA.120.047971.
    1. Tamis-Holland J.E., Jneid H., Reynolds H.R. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139:e891–e908.
    1. Su H., Yang M., Wan C. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;S0085-2538(20) 30369–0.
    1. Cheng Y., Luo R., Wang K. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829–838.
    1. Li Z., Wu M., Yao J., et al. Caution on Kidney Dysfunctions of COVID-19 Patients. medRxiv2020:2020.02.08.20021212.
    1. Goyal P., Choi J.J., Pinheiro L.C. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.
    1. Kern L., Mittenbuhler M.J., Vesting A.J., Ostermann A.L., Wunderlich C.M., Wunderlich F.T. Obesity-induced TNFalpha and IL-6 signaling: the missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers (Basel) 2018;11
    1. Desruisseaux M.S., Nagajyothi Trujillo ME, Tanowitz H.B., Scherer P.E. Adipocyte, adipose tissue, and infectious disease. Infect Immun. 2007;75:1066–1078.
    1. Maier H.E., Lopez R., Sanchez N. Obesity increases the duration of influenza a virus shedding in adults. J Infect Dis. 2018;218:1378–1382.
    1. Raj V.S., Mou H., Smits S.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254.
    1. Reinhold D., Kahne T., Steinbrecher A. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem. 2002;383:1133–1138.
    1. Simon D.W., Carcillo J.A. Practice Point 22 - infection-related hemophagocytic syndromes. Cohen J, Powderly WG, Opal SM, editors. Practice Point 22 - infection-related hemophagocytic syndromesInfect Dis (Fourth Edition): Elsevier. 2017;638-9:e1.

Source: PubMed

3
購読する